SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-126385
Filing Date
2024-11-13
Accepted
2024-11-13 16:30:23
Documents
53
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q virx-20240930.htm   iXBRL 10-Q 2131968
2 EX-10.1 virx-ex10_1.htm EX-10.1 26785
3 EX-31.1 virx-ex31_1.htm EX-31.1 10980
4 EX-31.2 virx-ex31_2.htm EX-31.2 10975
5 EX-32.1 virx-ex32_1.htm EX-32.1 5250
6 EX-32.2 virx-ex32_2.htm EX-32.2 5102
  Complete submission text file 0000950170-24-126385.txt   7849825

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT virx-20240930.xsd EX-101.SCH 1132985
55 EXTRACTED XBRL INSTANCE DOCUMENT virx-20240930_htm.xml XML 1366385
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51531 | Film No.: 241454854
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)